Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
165 participants
OBSERVATIONAL
2018-01-02
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic
NCT05056740
Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases
NCT05088473
Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients
NCT01380041
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
NCT04201470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neuromyelitis optica with anti-MOG
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Patients with Neuromyelitis optica with anti-AQP4
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Seronegative patients with Neuromyelitis optica
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Patients with recurrent-remitting multiple sclerosis
Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Progressive multiple sclerosis patients
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Symptomatic controls
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomarker analysis
Detection of biomarker in cerebrospinal fluid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Neuromyelitis Optica patients have been prospectively included in the OFSEP collection
* Multiple sclerosis patients, isolated myelitis or optic neuritis patients, and symptomatic controls whose samples will come from the "NEURO" collection of the Hospital Biological Collections Center,
* Patients have given their free consent for use of their samples in research
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Thouvenot
Role: PRINCIPAL_INVESTIGATOR
CHU Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nimes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIMAO/2017-01/ET-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.